Olema Pharmaceuticals Analyst Ratings
Buy Rating Affirmed for Olema Pharmaceuticals on Strong Clinical Trial Data for Palazestrant and Ribociclib Combination
Buy Rating Justified by Promising Efficacy and Safety Profile of Olema Pharmaceuticals' Drug Combination in Clinical Studies
Olema Pharmaceuticals Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Olema Pharmaceuticals, Maintains $30 Price Target
Promising Clinical Trial Results Bolster Buy Rating for Olema Pharmaceuticals
Olema Pharmaceuticals Analyst Ratings
HC Wainwright & Co. Maintains Buy on Olema Pharmaceuticals, Raises Price Target to $28
Analysts Are Bullish on Top Healthcare Stocks: Olema Pharmaceuticals (OLMA), Arcus Biosciences (RCUS)
Buy Rating on Olema Pharmaceuticals Amid Promising Clinical Trials and Strong Financial Position
Buy Rating Affirmed on Olema Pharmaceuticals Amid Promising Breast Cancer Treatment Advances and Strategic Novartis Collaboration
Promising Future for Olema Pharmaceuticals With Palazestrant in Breast Cancer Treatment: A Buy Rating
Buy Rating on Olema Pharmaceuticals Amidst Promising Oncology Developments and Competitive Edge
Olema Pharmaceuticals Analyst Ratings
Goldman Sachs Initiates Coverage On Olema Pharmaceuticals With Buy Rating, Announces Price Target of $24
Buy Rating for Olema Pharmaceuticals Based on Promising Palazestrant and Ribociclib Combination in ER+ Breast Cancer Treatment
Buy Rating Justified for Olema Pharmaceuticals Amidst Promising Trial Results and Significant Market Opportunity
Oppenheimer Sticks to Its Buy Rating for Olema Pharmaceuticals (OLMA)
Olema Pharmaceuticals Analyst Ratings
HC Wainwright & Co. Maintains Buy on Olema Pharmaceuticals, Lowers Price Target to $25